Quanterix Co. (NASDAQ:QTRX) Shares Acquired by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust increased its stake in Quanterix Co. (NASDAQ:QTRX) by 0.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 563,247 shares of the company’s stock after buying an additional 4,406 shares during the period. Emerald Mutual Fund Advisers Trust owned about 1.47% of Quanterix worth $7,300,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Quanterix by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,069,423 shares of the company’s stock worth $48,756,000 after purchasing an additional 14,390 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in Quanterix by 22.9% during the first quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock valued at $41,398,000 after buying an additional 326,876 shares in the last quarter. Easterly Investment Partners LLC lifted its holdings in Quanterix by 779.9% during the 2nd quarter. Easterly Investment Partners LLC now owns 692,746 shares of the company’s stock worth $9,151,000 after buying an additional 614,012 shares during the last quarter. Baillie Gifford & Co. grew its position in shares of Quanterix by 1.6% in the 2nd quarter. Baillie Gifford & Co. now owns 633,460 shares of the company’s stock worth $8,368,000 after acquiring an additional 10,105 shares in the last quarter. Finally, Farallon Capital Management LLC increased its holdings in shares of Quanterix by 156.0% in the 1st quarter. Farallon Capital Management LLC now owns 471,000 shares of the company’s stock valued at $11,097,000 after acquiring an additional 287,000 shares during the last quarter. 86.48% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on QTRX shares. Scotiabank reduced their price objective on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research note on Monday, August 12th. The Goldman Sachs Group decreased their price target on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating for the company in a report on Tuesday, July 9th. Finally, TD Cowen dropped their price objective on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating on the stock in a research note on Friday, August 9th.

Quanterix Price Performance

Shares of NASDAQ QTRX opened at $13.43 on Friday. The firm has a market capitalization of $515.44 million, a PE ratio of -12.79 and a beta of 1.36. Quanterix Co. has a 1-year low of $10.50 and a 1-year high of $29.70. The business’s fifty day moving average price is $12.71 and its two-hundred day moving average price is $14.09.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $34.38 million during the quarter, compared to analyst estimates of $34.19 million. Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. During the same period last year, the business earned ($0.16) EPS. Equities research analysts expect that Quanterix Co. will post -0.88 earnings per share for the current fiscal year.

Insider Activity

In other Quanterix news, Director David R. Walt bought 47,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average cost of $13.29 per share, for a total transaction of $624,630.00. Following the transaction, the director now directly owns 1,487,342 shares in the company, valued at $19,766,775.18. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.